Repurposing FDA-approved drugs as HIV-1 integrase inhibitors: an in silico investigation

References

• Agrawal, A., DeSoto, J., Fullagar, J. L., Maddali, K., Rostami, S., Richman, D. D., Pommier, Y., & Cohen, S. M. (2012). Probing chelation motifs in HIV integrase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 109(7), 2251–2256. https://doi.org/10.1073/pnas.1112389109
   PubMed Web of Science ®Google Scholar
• Aljazzar, H., & Leue, S. K. (2011). A heuristic search algorithm for finding the k shortest paths. Artificial Intelligence, 175(18), 2129–2154. https://doi.org/10.1016/j.artint.2011.07.003
   Web of Science ®Google Scholar
• Andrake, M., Skalka, A., & Merkel, G. (2018). Inhibitors of HIV-1 integrase multimerization.
   Google Scholar
• Anstett, K., Brenner, B., Mesplede, T., & Wainberg, M. A. (2017). HIV drug resistance against strand transfer integrase inhibitors. Retrovirology, 14(1), 36. https://doi.org/10.1186/s12977-017-0360-7
   PubMedGoogle Scholar
• Bacchi, A., Carcelli, M., Compari, C., Fisicaro, E., Pala, N., Rispoli, G., Rogolino, D., Sanchez, T. W., Sechi, M., Sinisi, V., & Neamati, N. (2011). Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. Journal of Medicinal Chemistry, 54(24), 8407–8420. https://doi.org/10.1021/jm200851g
   PubMed Web of Science ®Google Scholar
• Barzegar, A., & Hamidi, H. (2017). Quantitative structure-activity relationships study of potent pyridinone scaffold derivatives as HIV-1 integrase inhibitors with therapeutic applications. Journal of Theoretical and Computational Chemistry, 16(5), 1750038. https://doi.org/10.1142/S0219633617500389
   Web of Science ®Google Scholar
• Brooks, K. M., Sherman, E. M., Egelund, E. F., Brotherton, A., Durham, S., Badowski, M. E., & Cluck, D. B. (2019). Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacotherapy, 39(5), 576–598. https://doi.org/10.1002/phar.2246
   PubMed Web of Science ®Google Scholar
• Carswell, C. I., Plosker, G. L., & Jarvis, B. (2002). Rosuvastatin. Drugs, 62(14), 2075–2085. https://doi.org/10.2165/00003495-200262140-00008
   PubMed Web of Science ®Google Scholar
• Carter, G. C., Bernstone, L., Sangani, D., Bee, J. W., Harder, T., & James, W. (2009). HIV entry in macrophages is dependent on intact lipid rafts. Virology, 386(1), 192–202. https://doi.org/10.1016/j.virol.2008.12.031
   PubMed Web of Science ®Google Scholar
• CfsSubsetEval. (XXXX). CfsSubsetEval (weka-dev 3.9.5 API). https://weka.sourceforge.io/doc.dev/weka/attributeSelection/CfsSubsetEval.html.
   Google Scholar
• Cheng, Z., Zhang, Y., & Fu, W. (2010). QSAR study of carboxylic acid derivatives as HIV-1 Integrase inhibitors. European Journal of Medicinal Chemistry, 45(9), 3970–3980. https://doi.org/10.1016/j.ejmech.2010.05.052
   PubMed Web of Science ®Google Scholar
• Chu, W.-T., Zhang, J.-L., Zheng, Q.-C., Chen, L., Xue, Q., & Zhang, H.-X. (2013). Insights into the drug resistance induced by the BaDHPS mutations: molecular dynamic simulations and MM/GBSA studies. Journal of Biomolecular Structure & Dynamics, 31(10), 1127–1136. https://doi.org/10.1080/07391102.2012.726529
   PubMed Web of Science ®Google Scholar
• Darnag, R., Minaoui, B., & Fakir, M. (2013). Pattern recognition system based on support vector machines: HIV-1 integrase inhibitors application. Control Theory Informatics, 3, 1–8.
   Google Scholar
• del Real, G., Jiménez-Baranda, S., Mira, E., Lacalle, R. A., Lucas, P., Gómez-Moutón, C., Alegret, M., Peña, J. M., Rodríguez-Zapata, M., Alvarez-Mon, M., Martínez-A, C., & Mañes, S. (2004). Statins inhibit HIV-1 infection by down-regulating Rho activity. The Journal of Experimental Medicine, 200(4), 541–547. https://doi.org/10.1084/jem.20040061
   PubMed Web of Science ®Google Scholar
• Delaney, M. (2006). History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology, 3(S1), S6. https://doi.org/10.1186/1742-4690-3-S1-S6
   PubMedGoogle Scholar
• Delelis, O., Carayon, K., Saïb, A., Deprez, E., & Mouscadet, J. F. (2008). Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology, 5, 114. https://doi.org/10.1186/1742-4690-5-114
   PubMed Web of Science ®Google Scholar
• Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., Zhang, Y., Li, W., Furtek, C., Mahoney, E., Harper Mozley, L., Mo, Y., Sur, C., & Michelson, D. (2019). Randomized trial of verubecestat for prodromal Alzheimer's disease. The New England Journal of Medicine, 380(15), 1408–1420. https://doi.org/10.1056/NEJMoa1812840
   PubMed Web of Science ®Google Scholar
• Gavegnano, C., Detorio, M., Montero, C., Bosque, A., Planelles, V., & Schinazi, R. F. (2014). Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrobial Agents and Chemotherapy, 58(4), 1977–1986.
   PubMed Web of Science ®Google Scholar
• Giguère, J.-F., & Tremblay, M. J. (2004). Statin compounds reduce Human Immunodeficiency Virus Type 1 replication by preventing the interaction between virion-associated host Intercellular Adhesion Molecule 1 and its natural cell surface ligand LFA-1. Journal of Virology, 78(21), 12062–12065. https://doi.org/10.1128/JVI.78.21.12062-12065.2004
   PubMed Web of Science ®Google Scholar
• González-Medina, M., & Medina-Franco, J. L. (2017). Platform for unified molecular analysis: PUMA. Journal of Chemical Information and Modeling, 57(8), 1735–1740. https://doi.org/10.1021/acs.jcim.7b00253
   PubMed Web of Science ®Google Scholar
• Gupta, P., Garg, P., & Roy, N. (2012). Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach. Chemical Biology & Drug Design, 79(5), 835–849. https://doi.org/10.1111/j.1747-0285.2012.01326.x
   PubMed Web of Science ®Google Scholar
• Hajimahdi, Z., & Zarghi, A. (2016). Progress in HIV-1 integrase inhibitors: a review of their chemical structure diversity. Iranian Journal of Pharmaceutical Research: IJPR, 15(4), 595–628.
   PubMed Web of Science ®Google Scholar
• Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., & Witten, I. H. (2009). The WEKA data mining software. ACM SIGKDD Explorations Newsletter, 11(1), 10–18. https://doi.org/10.1145/1656274.1656278
   Google Scholar
• Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010). Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 20057–20062. https://doi.org/10.1073/pnas.1010246107
   PubMed Web of Science ®Google Scholar
• Hightower, K. E., Wang, R., Deanda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R. (2011). Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrobial Agents and Chemotherapy, 55(10), 4552–4559. https://doi.org/10.1128/AAC.00157-11
   PubMed Web of Science ®Google Scholar
• Ingale, K. B., & Bhatia, M. S. (2011). HIV-1 integrase inhibitors: a review of their chemical development. Antiviral Chemistry & Chemotherapy, 22(3), 95–105. https://doi.org/10.3851/IMP1740
   PubMedGoogle Scholar
• Jacobson, K., & Ogbuagu, O. (2018). Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting. Medicine, 97(43), e13016. https://doi.org/10.1097/MD.0000000000013016
   PubMed Web of Science ®Google Scholar
• Johns, B. A., Weatherhead, J. G., Hakogi, T., & Aoyama, Y. (2014). Chemical compounds used as HIV integrase inhibitors.
   Google Scholar
• Klebe, G., Abraham, U., & Mietzner, T. (1994). Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. Journal of Medicinal Chemistry, 37(24), 4130–4146. https://doi.org/10.1021/jm00050a010
   PubMed Web of Science ®Google Scholar
• Ko, G. M. (2012). Differential evolution-binary particle swarm optimization algorithm for the analysis of aryl β-diketo acids for HIV-1 integrase inhibition [Paper presentation]. 2012 IEEE Congress on Evolutionary Computation, CEC 2012 https://doi.org/10.1109/CEC.2012.6256578
   Google Scholar
• L, M. (2014). Stabilization of the integrase-DNA complex by Mg2+ ions and prediction of key residues for binding HIV-1 integrase inhibitors. Proteins, 82, 466–478.
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling, 51(10), 2778–2786. https://doi.org/10.1021/ci200227u
   PubMed Web of Science ®Google Scholar
• Li, X., & Vince, R. (2006). Synthesis and biological evaluation of purine derivatives incorporating metal chelating ligands as HIV integrase inhibitors. Bioorganic & Medicinal Chemistry, 14(16), 5742–5755. https://doi.org/10.1016/j.bmc.2006.04.011
   PubMed Web of Science ®Google Scholar
• Markwick, P. R. L., & McCammon, J. A. (2011). Studying functional dynamics in bio-molecules using accelerated molecular dynamics. Physical Chemistry Chemical Physics: PCCP, 13(45), 20053–20065.
   PubMed Web of Science ®Google Scholar
• Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157. https://doi.org/10.2174/157340911795677602
   PubMed Web of Science ®Google Scholar
• Miller, B. R., McGee, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. https://doi.org/10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Miri, L., Bouvier, G., Kettani, A., Mikou, A., Wakrim, L., Nilges, M., & Malliavin, T. E. (2014). Stabilization of the integrase-DNA complex by Mg2+ ions and prediction of key residues for binding HIV-1 integrase inhibitors. Proteins Struct Proteins, 82(3), 466–478. https://doi.org/10.1002/prot.24412
   PubMed Web of Science ®Google Scholar
• Mouscadet, J. F., & Tchertanov, L. (2009). Raltegravir: molecular basis of its mechanism of action. European Journal of Medical Research, 14(Suppl 3), 5. https://doi.org/10.1186/2047-783X-14-S3-5
   PubMedGoogle Scholar
• Neamati, N., Lin, Z., Karki, R. G., Orr, A., Cowansage, K., Strumberg, D., Pais, G. C. G., Voigt, J. H., Nicklaus, M. C., Winslow, H. E., Zhao, H., Turpin, J. A., Yi, J., Skalka, A. M., Burke, T. R., & Pommier, Y. (2002). Metal-dependent inhibition of HIV-1 integrase. Journal of Medicinal Chemistry, 45(26), 5661–5670. https://doi.org/10.1021/jm0201417
   PubMed Web of Science ®Google Scholar
• Neves, B. J., Braga, R. C., Melo-Filho, C. C., Moreira-Filho, J. T., Muratov, E. N., & Andrade, C. H. (2018). QSAR-based virtual screening: advances and applications in drug discovery. Frontiers in Pharmacology, 9, 1275. https://doi.org/10.3389/fphar.2018.01275
   PubMed Web of Science ®Google Scholar
• Oh, J. W., Oh, Y. T., Kim, D. J., & Shin, C. G. (1997). Characterization of mutants of human immunodeficiency virus type 1 integrase mutants expressed in Escherichia coli. Molecules and Cells, 7(5), 688–693.
   PubMed Web of Science ®Google Scholar
• Ono, A., & Freed, E. O. (2001). Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proceedings of the National Academy of Sciences of the United States of America, 98(24), 13925–13930. https://doi.org/10.1073/pnas.241320298
   PubMed Web of Science ®Google Scholar
• Passos, D. O., Li, M., Jóźwik, I. K., Zhao, X. Z., Santos-Martins, D., Yang, R., Smith, S. J., Jeon, Y., Forli, S., Hughes, S. H., Burke, T. R., Craigie, R., & Lyumkis, D. (2020). Structural basis for strand-transfer inhibitor binding to HIV intasomes. Science (New York, NY), 367(6479), 810–814. https://doi.org/10.1126/science.aay8015
   Google Scholar
• Passos, D. O., Li, M., Yang, R., Rebensburg, S. V., Ghirlando, R., Jeon, Y., Shkriabai, N., Kvaratskhelia, M., Craigie, R., & Lyumkis, D. (2017). Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. Science (New York, NY), 355(6320), 89–92. https://doi.org/10.1126/science.aah5163
   Google Scholar
• Pearlman, D. A., Case, D. A., Caldwell, J. W., Ross, W. S., Cheatham, T. E., DeBolt, S., Ferguson, D., Seibel, G., & Kollman, P. (1995). AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Computer Physics Communications, 91(1–3), 1–41. https://doi.org/10.1016/0010-4655(95)00041-D
   Web of Science ®Google Scholar
• Pennington, L. D., & Moustakas, D. T. (2017). The necessary Nitrogen atom: a versatile high-impact design element for multiparameter optimization. Journal of Medicinal Chemistry, 60(9), 3552–3579. https://doi.org/10.1021/acs.jmedchem.6b01807
   PubMed Web of Science ®Google Scholar
• Pierce, L. C. T., Salomon-Ferrer, R., de Oliveira, C. A. F., McCammon, J. A., & Walker, R. C. (2012). Routine access to millisecond time scale events with accelerated molecular dynamics. Journal of Chemical Theory and Computation, 8(9), 2997–3002. https://doi.org/10.1021/ct300284c
   PubMed Web of Science ®Google Scholar
• Rathi, L. G., Kashaw, S. K., Agrawal, R. K., & Mishra, P. (2001). Comparative Molecular Field Analysis (CoMFA): a modern approach towards drug design. Indian Journal of Pharmaceutical Sciences, 63, 367–370.
   Google Scholar
• Rücker, C., Rücker, G., & Meringer, M. (2007). Y-randomization and its variants in QSPR/QSAR. Journal of Chemical Information and Modeling, 47(6), 2345–2357. https://doi.org/10.1021/ci700157b
   PubMed Web of Science ®Google Scholar
• Schroeder, M. A. (2020). A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Advances, 4, 1657–1669.
   Web of Science ®Google Scholar
• Svetnik, V., Liaw, A., Tong, C., Culberson, J. C., Sheridan, R. P., & Feuston, B. P. (2003). Random Forest: a classification and regression tool for compound classification and QSAR modeling. Journal of Chemical Information and Computer Sciences, 43(6), 1947–1958.
   PubMedGoogle Scholar
• Trivedi, J., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020). Recent advances in the development of integrase inhibitors for HIV treatment. Current HIV/AIDS Reports, 17(1), 63–75. https://doi.org/10.1007/s11904-019-00480-3
   PubMed Web of Science ®Google Scholar
• Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. Molecular Informatics, 29(6-7), 476–488. https://doi.org/10.1002/minf.201000061
   PubMed Web of Science ®Google Scholar
• Underwood, M. R., Johns, B. A., Sato, A., Martin, J. N., Deeks, S. G., & Fujiwara, T. (2012). The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. Journal of Acquired Immune Deficiency Syndromes (1999), 61(3), 297–301. https://doi.org/10.1097/QAI.0b013e31826bfd02
   PubMed Web of Science ®Google Scholar
• Veerasamy, R. (2011). Validation of QSAR models - strategies and importance. International Journal of Drug Design & Disocovery, 2, 511–519.
   Google Scholar
• Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., … Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082. https://doi.org/10.1093/nar/gkx1037
   PubMed Web of Science ®Google Scholar
• Yan, A., Xuan, S., & Hu, X. (2012). Classification of active and weakly active ST inhibitors of HIV-1 integrase using a Support Vector Machine. Combinatorial Chemistry & High Throughput Screening, 15(10), 792–805. https://doi.org/10.2174/138620712803901108
   PubMed Web of Science ®Google Scholar
• Zakariazadeh, M., Barzegar, A., Soltani, S., & Aryapour, H. (2015). Developing 2D-QSAR models for naphthyridine derivatives against HIV-1 integrase activity. Medicinal Chemistry Research, 24(6), 2485–2504. https://doi.org/10.1007/s00044-014-1305-5
   Web of Science ®Google Scholar